Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to perform a prospective, randomized study for the reduction of
atrial fibrillation (AF) burden and progression, targeting metabolic upstream therapies. The
study aims to determine if metformin and/or lifestyle/risk factor modifications reduce AF
burden and progression. A secondary aim will attempt to determine clinical, genomic, and
biomarker predictors of AF progression that can be used to personalize upstream therapies.
This is a prospective randomized open-label blinded endpoint (PROBE) 2x2 factorial study of
metformin extended release up to 750 mg twice daily and lifestyle and risk factor
modification (LRFM) in patients with implanted pacemakers or defibrillators with atrial leads
and at least 1 ≥5 minute episode of AF over the prior 3 months.